RET Fusion Treatment: Pralsetinib - Targeted Therapies in Lung Cancer 2023

The Future of RET+ NSCLC Treatment - Targeted Therapies in Lung Cancer 2023Подробнее

Rare Fusions in NSCLC: RET - Targeted Therapies in Lung Cancer 2023Подробнее

RET Fusion Treatment: Selpercatinib - Targeted Therapies in Lung Cancer 2023Подробнее

RET fusion-positive mNSCLC: selpercatinib and pralsetinibПодробнее

Safety and Toxicity of Selpercatinib Versus Pralsetinib - Targeted Therapies in Lung Cancer 2023Подробнее

Pralsetinib in Chinese patients with advanced RET fusion+ NSCLCПодробнее

Dr Boman Dhabhar | Safety and efficacy of Pralsetinib in RET fusion positiveПодробнее

Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung CancersПодробнее

Selpercatinib and Pralsetinib in RET + Disease - Lung Cancer Video LibraryПодробнее

Treatments for RET+ NSCLC: Selpercatinib vs. Pralsetinib - 2022 Program: Targeted Therapies ForumПодробнее

RET fusion-positive NSCLC: Delivering targeted treatment | Panel discussionПодробнее